


**We Claim:**

1. A compound selected from the group consisting of a compound of Formula I :



Formula I


wherein:

W is a CH group or a N atom;

Z is N or C;

B and D are selected independently from CH and N, with the proviso that at least one of B and D is CH and with the further proviso that one of B and D can represent N only when W and Z are both other than N;

A is a group of Formula II, such that group A contains at least 1 N atom;



Formula II

R<sub>1</sub> is selected from the group consisting of H, alkyl including C(1-12)alkyl, alkyloxy, alkanoyl, aminoalkylenyl, alkylaminoalkylenyl, a hydroxyalkylenyl group, an alkyloxyalkylenyl group, a cycloalkyl group, a cycloalkylalkylenyl group, a heterocycloalkyl group, a heterocycloalkylenyl group, an aryl group, a heteroaryl group, an amido group, a thioamido group, an arylcarbonyl group and an arylsulfonyl group;

$R_2$  and  $R_3$  are independently selected from the group consisting of H, alkyl, cycloalkyl, alkenyl and optionally-substituted benzyl ; or  $R_2$  and  $R_3$ , together with the nitrogen atom to which they are attached, may form a mono- or bi-cyclic group containing up to 10 carbon atoms and which, in addition, may contain a second heteroatom selected from the group consisting of N, S and O, and which may contain one or more substituents selected from the group consisting of alkyl, hydroxy, hydroxymethyl, alkyloxymethyl, amino and substituted amino;

$R_4$  is selected from the group consisting of H, alkyl and cycloalkyl;

$CR_5$  represents a group selected from  $-CH_2-$ ,  $CH(OH)-$ ,  $-C(O)-$ ,  $-CH(alkyl)-$  and  $-CH(alkyloxy)-$ ;

$R_6$  is selected from the group consisting of H, alkyl, aryl, halogen, hydroxy, alkyloxy, amino, monoalkylamino and di-substitutedalkylamino;

and salts and solvates thereof.

2. A compound according to claim 1 wherein  $R_1$  is an aryl group.
3. A compound according to claim 1 wherein  $R_1$  is a heterocycloalkyl group.
4. A compound according to claim 3 wherein  $R_1$  is tetrahydropyranyl.
5. A compound according to claim 1 wherein  $R_1$  is a cycloalkyl group.
6. A compound according to claim 1 wherein  $R_1$  is an alkyl group.
7. A compound according to claim 6 wherein  $R_1$  is isopropyl.

8. A compound according to claim 1, wherein A is a group selected from a (mono- or di-) substituted aminoalkylenyl, an N-cycloalkyl and an N-cycloalkylalkylenyl.

9. A compound according to claim 8, wherein A is N,N-dimethylaminoethyl, N,N-diethylaminoethyl, N-methyl-N-ethylaminoethyl, N-isopropylaminoethyl, N,N-dipropylaminoethyl, N-cyclopropylaminoethyl, N-cyclopropylmethylaminoethyl, N-methyl-N-cyclopropylamino, pyrrolidinoethyl, pyrrolinoethyl, piperidinoethyl, morpholinoethyl, thiomorpholinoethyl or piperazinoethyl.

10. A compound according to claim 1, wherein the ring system formed by selection of B, D, W and Z is a ring system selected from indole, indoline, indazole, benzotriazole, benzimidazole, 7-aza-indole, and 5-aza-indole.

11. A compound according to claim 10, wherein R6 is selected from H and alkyl, and R4 is H.

12. A compound according to claim 11, wherein the ring system formed by selection of B, D, W and Z,  $R_4$  and  $R_6$  is a ring system selected from indole and indazole.

13. A compound according to claim 11, wherein said ring system is indole.

14. A compound according to claim 1, selected from the group consisting of:

- 6-(2-(N,N-Dimethylamino)ethyl)-1H-indole;
- 6-(2-(N,N-Dimethylamino)ethyl)-1-isopropyl-indole;
- 6-(2-(N,N-Diethylamino)ethyl)-indole;
- 6-(2-(N,N-Diethylamino)ethyl)-1-isopropyl-indole;
- 6-(2-(N,N-Diethylamino)ethyl)-1-dimethylaminocarbonyl-indole;
- 6-(2-(N,N-Dimethylamino)ethyl)-1-(tetrahydrothiopyran-4-yl)-indole;
- 6-(2-(N,N-Dimethylamino)ethyl)-1-(tetrahydropyran-4-yl)-indole;
- 6-(2-(N,N-Dimethylamino)ethyl)-1-isopropyl-1H-indazole;
- 6-(2-(N,N-Dimethylaminoethyl)-1-(3-pyridinyl)-indole;
- 6-(2-(N,N-Dimethylaminoethyl)-1-(3-thienyl)-indole; and
- 6-(2-(N,N-Dimethylaminoethyl)-1-(4-fluorophenyl)-indole.

15. A compound according to claim 14, selected from the group consisting of:

6-(2-(N,N-Dimethylamino)ethyl)-1H-indole;

6-(2-(N,N-Dimethylamino)ethyl)-1-isopropyl-indole;

6-(2-(N,N-Diethylamino)ethyl)-1-isopropyl-indole;

6-(2-(N,N-Diethylamino)ethyl)-1-dimethylaminocarbonyl-indole;

6-(2-(N,N-Dimethylamino)ethyl)-1-(tetrahydrothiopyran-4-yl)-indole;

6-(2-(N,N-Dimethylamino)ethyl)-1-(tetrahydropyran-4-yl)-indole;

6-(2-(N,N-Dimethylamino)ethyl)-1-(3-pyridinyl)-indole;

6-(2-(N,N-Dimethylamino)ethyl)-1-(3-thienyl)-indole; and

6-(2-(N,N-Dimethylamino)ethyl)-1-(4-fluorophenyl)-indole.

16. A composition comprising a therapeutically effective amount of a compound according to claim 1, and a pharmaceutically acceptable carrier.

17. A method for treating a patient having a medical condition for which stimulation of the 5-HT<sub>1D</sub> receptor is indicated, comprising the step of administering to the patient a pharmaceutical composition as defined in claim 16.

18. A method according to claim 17, wherein the medical condition is migraine.

claims2.wpd